August 01, 2022
Video
“UGN-102 may offer a patient-centered therapeutic approach, more patient centered than standard treatments like surgery,” says Angela M. Stover, PhD.
July 29, 2022
Article
The application is supported by findings from the phase 2/3 QUILT-3.032 trial.
July 28, 2022
“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.
July 26, 2022
Study results presented at the 2022 AUA Annual Meeting showed that pembrolizumab plus cabazitaxel and gemcitabine had promising early efficacy in heavily pretreated patients with high-risk non–muscle invasive urothelial carcinoma.
The combination induced a response in nearly two-thirds of patients with unresectable locally advanced or metastatic urothelial cancer when used in the frontline setting.
July 22, 2022
“Histologic variants do express Nectin-4 and Trop-2, the targets of antibody-drug conjugates that are FDA-approved in bladder cancer,” says Fed Ghali, MD.
July 21, 2022
Fed Ghali, MD, discusses the outlook for patients with variant histology bladder cancer and how antibody-drug conjugates may provide a new treatment option in this setting.
FDA talks have led to a voluntary pause on the development of Vicineum for bladder cancer in the United States.
July 15, 2022
"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.
July 14, 2022
The analysis showed promising signs of clinical activity with cabazitaxel/gemcitabine plus pembrolizumab in patients with docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts.
